Cyclo Therapeutics (CYTH) AI Stock Analysis

• Market Cap: $20.73M
• Dividend Yield: N/A
• Average Volume (3M): 119.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.48
• Revenue Growth: -8.52%
• EPS Growth: 46.35%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 69
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.90
• Shares Outstanding: 28,614,000
• 10 Day Avg. Volume: 56,174
• 30 Day Avg. Volume: 119,082
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 23.13
• Price to Cash Flow (P/CF): -0.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.64
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 34.71
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Cyclo Therapeutics is currently facing severe financial challenges with persistent losses, declining revenues, and increasing liabilities. While technical indicators show some short-term recovery potential, the lack of profitability and weak valuation metrics significantly impact the stock's attractiveness.

Positive Factors

Clinical Trials

The company announced it has completed enrollment for its 108-patient pivotal phase 3 trial of its lead drug candidate.

Patents

The company received notice from the European Patent Office of a decision to grant a European patent application.

Negative Factors

Earnings

EPS was $(0.21), versus our and consensus estimate of $(0.17).

Cyclo Therapeutics Business Overview & Revenue Model

Company Description

Cyclo Therapeutics, Inc. (CYTH) is a biotechnology company focused on developing treatments for rare and serious diseases. Specializing in the use of cyclodextrins, the company aims to advance its proprietary Trappsol® Cyclo™, a treatment for Niemann-Pick Disease Type C (NPC), a rare genetic disorder. Cyclo Therapeutics operates within the pharmaceutical and healthcare sectors, leveraging its expertise in cyclodextrin technology to address complex medical needs.

How the Company Makes Money

Cyclo Therapeutics generates revenue primarily through the development and commercialization of its pharmaceutical products, particularly Trappsol® Cyclo™. The company's revenue model includes income from product sales, potential collaborations with other pharmaceutical companies, and licensing agreements. Significant partnerships with research institutions and other biotech companies might also contribute to its earnings, as these collaborations can facilitate the advancement and commercialization of its drug candidates. Additionally, the company may receive funding through grants and research subsidies, given its focus on rare diseases. However, as of now, Cyclo Therapeutics is primarily in the research and development stage, which may limit immediate revenue generation until its products are approved and commercialized.

Cyclo Therapeutics Financial Statement Overview

Summary

Cyclo Therapeutics faces significant financial challenges across income, balance sheet, and cash flow statements. Persistent losses and declining revenues alongside rising liabilities and negative free cash flow highlight the need for strategic reassessment to improve financial health and sustainability.

Income Statement

The income statement shows a significant decline in revenue and profitability. The TTM period reveals a negative gross profit margin and a worsening net loss, indicating challenges in cost management and revenue generation. The consistent decline in revenue over the years suggests difficulties in sustaining growth.

Balance Sheet

The balance sheet shows a deteriorating financial position with negative stockholders' equity in the latest period. This indicates that liabilities exceed assets, posing a risk to financial stability. The increase in liabilities and the significant drop in equity ratio highlight leverage concerns.

Cash Flow

The cash flow statement shows negative free cash flow, which has worsened over time. The operating cash flow to net income ratio is negative, indicating cash flow issues. The consistent negative free cash flow growth rate underscores challenges in generating cash from operations.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
1.08M	1.38M	1.59M	903.38K	1.01M
	Gross Profit
977.95K	1.24M	1.43M	836.98K	931.71K
	EBIT
-20.05M	-15.61M	-14.27M	-8.96M	-7.39M
	EBITDA
-20.03M	-15.60M	-14.27M	-8.95M	-7.39M
	Net Income Common Stockholders
-20.06M	-15.28M	-14.31M	-8.92M	-7.67M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
9.25M	1.54M	16.61M	12.85M	2.78M
	Total Assets
13.25M	4.22M	19.52M	14.19M	4.11M
	Total Debt
1.03M	0.00	170.99K	194.44K	52.51K
	Net Debt
-8.21M	-1.54M	-16.44M	-12.65M	-2.73M
	Total Liabilities
8.49M	3.48M	3.85M	3.74M	3.18M
	Stockholders Equity
4.76M	734.54K	15.67M	10.45M	935.98K
Cash Flow		Free Cash Flow
-16.19M	-15.13M	-15.03M	-8.59M	-6.59M
	Operating Cash Flow
-16.19M	-15.11M	-15.01M	-8.54M	-6.59M
	Investing Cash Flow
-2.42K	38.17K	14.82K	-14.05K	36.13K
	Financing Cash Flow
23.89M	6.78K	18.76M	18.62M	7.12M

Cyclo Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYTH, the sentiment is Neutral. The current price of 0.72 is above the 20-day moving average (MA) of 0.71, below the 50-day MA of 0.79, and below the 200-day MA of 0.86, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 47.87 is Neutral, neither overbought nor oversold. The STOCH value of 66.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CYTH.

Cyclo Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUPH	69 Neutral	$1.12B	211.92	1.52%	―	33.97%	―
Sector *	51 Neutral	$5.31B	3.39	-40.42%	2.90%	18.11%	2.25%
BCRX	50 Neutral	$1.75B	―	18.68%	―	36.00%	63.50%
AXSM	46 Neutral	$5.18B	―	-231.63%	―	42.53%	-15.29%
ABUS	41 Neutral	$629.97M	―	-68.76%	―	-65.98%	14.00%
CLSD	40 Underperform	$65.05M	―	91.63%	―	-79.77%	10.85%
CYTH	33 Underperform	$20.73M	―	184.06%	―	-8.52%	46.35%